Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to chronic kidney disease associated with type 2 diabetes. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated “April 30, 2024”.

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 227    

Filtered results: 227

Baseline kidney function, albuminuria, and urine albumin-creatinine ratio reduction with finerenone, empagliflozin, or both Post hoc analyses of the CONFIDENCE trial

Publication - Mottl A., et al, JASN. 2025

Mottl A, 09 12 2025

Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function

Publication - Katamaya S., et al, Journal of Diabetes and its Complications. 2025

Katayama S, 09 12 2025

Finerenone in patients with severe heart failure: The FINEARTS-HF trial

Inciardi RM., et al, European Journal of Heart Failure. 2025

Inciardi RM, 09 12 2025

Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction

Publication - Vadugantathan M., et al, Nature Medicine. 2025

Vaduganathan M , 09 12 2025

Navigating disparities and overcoming barriers to access diabetic kidney disease therapies: A proposed multifactorial approach

Petrosyan R., et al, Nephron. 2025

Petrosyan R, 09 12 2025

New and emerging non-immunosuppressive drug therapies for primary adult glomerular diseases

Mushlailov V., et al, Kidney Medicine. 2025

Mushailov V, 09 12 2025

Risk of hyperkalemia with empagliflozin, finerenone, or both: Secondary analysis of CONFIDENCE randomized trial

Publication - Agarwal R., et al, JACC. 2025

Agarwal R, 09 12 2025

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Tuttle KR., et al, Diabetes Obes Metab. 2025

Tuttle KR, 31 10 2025

Dosing, treatment patterns, and safety of finerenone use in routine care: an interim analysis of the prospective, real-world, and observational FINE-REAL study

Wheeler DC., et al, Clinical Kidney Journal. 2025

Wheeler DC, 31 10 2025

Post hoc analyses of DKD clinical trials in ethnic minorities (asian, hispanic, black): A narrative review

Hsiao L., et al, Clinical Therapeutics. 2025

Hsiao L, 31 10 2025